Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takuya Sho

Showing results (31-40 of 119) with videos related to

Pageof 12
Sort By:
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 31, 2020
Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19Goki Suda, Koji Ogawa, Megumi Kimura, et al.
Frontiers in Nutrition|March 6, 2026
Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver diseaseTakatsugu Tanaka, Goki Suda, Masatsugu Ohara, et al.
Internal Medicine (Tokyo, Japan)|December 21, 2018
The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor TreatmentGoki Suda, Masato Nakai, Takuya Sho, et al.
Drugs in R&D|June 3, 2017
A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular CarcinomaTakuya Sho, Mitsuru Nakanishi, Kenichi Morikawa, et al.
Internal Medicine (Tokyo, Japan)|November 20, 2018
Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three CasesTakuya Sho, Goki Suda, Megumi Kimura, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|October 26, 2020
Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinomaTaku Shigesawa, Goki Suda, Megumi Kimura, et al.
Cancers|July 24, 2021
Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRIAkinori Kubo, Goki Suda, Megumi Kimura, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 24, 2021
Treatment outcomes of stereotactic body radiation therapy using a real-time tumor-tracking radiotherapy system for hepatocellular carcinomasYusuke Uchinami, Norio Katoh, Daisuke Abo, et al.
Virology Journal|June 19, 2026
HBsAg glycan isomer predicts on-treatment HBsAg decline in low-HBsAg chronic hepatitis B on nucleos(t)ide therapyDaisuke Yokoyama, Goki Suda, Masatsugu Ohara, et al.
Analytical Chemistry|October 3, 2019
Comparative Glycomic Analysis of Sialyl Linkage Isomers by Sialic Acid Linkage-Specific Alkylamidation in Combination with Stable Isotope Labeling of α2,3-Linked Sialic Acid ResiduesHisatoshi Hanamatsu, Takashi Nishikaze, Hiroki Tsumoto, et al.
Pageof 12

Showing results (31-40 of 119) with videos related to

Sort By:
Pageof 12
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 31, 2020
Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19Goki Suda, Koji Ogawa, Megumi Kimura, et al.
Frontiers in Nutrition|March 6, 2026
Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver diseaseTakatsugu Tanaka, Goki Suda, Masatsugu Ohara, et al.
Internal Medicine (Tokyo, Japan)|December 21, 2018
The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor TreatmentGoki Suda, Masato Nakai, Takuya Sho, et al.
Drugs in R&D|June 3, 2017
A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular CarcinomaTakuya Sho, Mitsuru Nakanishi, Kenichi Morikawa, et al.
Internal Medicine (Tokyo, Japan)|November 20, 2018
Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three CasesTakuya Sho, Goki Suda, Megumi Kimura, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|October 26, 2020
Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinomaTaku Shigesawa, Goki Suda, Megumi Kimura, et al.
Cancers|July 24, 2021
Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRIAkinori Kubo, Goki Suda, Megumi Kimura, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 24, 2021
Treatment outcomes of stereotactic body radiation therapy using a real-time tumor-tracking radiotherapy system for hepatocellular carcinomasYusuke Uchinami, Norio Katoh, Daisuke Abo, et al.
Virology Journal|June 19, 2026
HBsAg glycan isomer predicts on-treatment HBsAg decline in low-HBsAg chronic hepatitis B on nucleos(t)ide therapyDaisuke Yokoyama, Goki Suda, Masatsugu Ohara, et al.
Analytical Chemistry|October 3, 2019
Comparative Glycomic Analysis of Sialyl Linkage Isomers by Sialic Acid Linkage-Specific Alkylamidation in Combination with Stable Isotope Labeling of α2,3-Linked Sialic Acid ResiduesHisatoshi Hanamatsu, Takashi Nishikaze, Hiroki Tsumoto, et al.
Pageof 12